796-66-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluorouridine 5'-phosphate is used as an anticancer agent for its ability to disrupt the synthesis of RNA and DNA, thereby inhibiting the growth of cancer cells. It is particularly effective against a variety of solid tumors, including those in the colon, rectum, breast, stomach, and head and neck.
Used in Nucleic Acid Synthesis:
In the field of molecular biology, 5-fluorouridine 5'-phosphate is utilized as a building block for the synthesis of modified nucleic acids. Its incorporation into RNA or DNA can lead to the development of new therapeutic agents or the study of nucleic acid structure and function.
Used in Enzyme Inhibition:
5-Fluorouridine 5'-phosphate is used as an inhibitor of certain enzymes involved in nucleic acid metabolism. By targeting these enzymes, it can help regulate cellular processes and potentially lead to the development of new drugs for the treatment of various diseases.
Used in Drug Development:
In the development of new pharmaceuticals, 5-fluorouridine 5'-phosphate serves as a key intermediate in the synthesis of various drugs. Its unique properties allow for the creation of novel compounds with potential therapeutic applications in different areas of medicine.

Upstream product

• 464169-57-1 C₁₁H₁₈FN₂O₁₅P₃ 

Relevant academic research and scientific papers

Bisphosphonate derivatives of nucleoside antimetabolites: Hydrolytic stability and hydroxyapatite adsorption of 5′-β,γ-methylene and 5′-β,γ-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine

(Chemical Equation Presented) Kinetics of the hydrolytic reactions of four bisphosphonate derivatives of nucleoside antimetabolites, viz., 5-fluorouridine 5′-β,γ-(1-hydroxyethylidene) triphosphate (4), 5-fluorouridine 5′-β,γ-methylene triphosphate (5), ara-cytidine 5′-β,γ-(1-hydroxyethylidene) triphosphate (6), and ara-cytidine 5′-β,γ-methylene triphosphate (7), have been studied over a wide pH range (pH 1.0-8.5) at 90°C. With each compound, the disappearance of the starting material was accompanied by formation of the corresponding nucleoside 5′-monophosphate, the reaction being up to 2 orders of magnitude faster with the β,γ-(1-hydroxyethylidene) derivatives (4, 6) than with their β,γ-methylene counterparts (5, 7). With compound 7, deamination of the cytosine base competed with the phosphate hydrolysis at pH 3-6. The measurements at 37°C (pH 7.4) in the absence and presence of divalent alkaline earth metal ions (Mg2+ and Ca2+) showed no sign of metal ion catalysis. Under these conditions, the initial product, nucleoside 5′-monophosphate, underwent rapid dephosphorylation to the corresponding nucleoside. Hydrolysis of the β,γ-methylene derivatives (5, 7) to the corresponding nucleoside 5′-monophosphates was markedly faster in mouse serum than in aqueous buffer (pH 7.4), the rate-acceleration being 5600- and 3150-fold with 5 and 7, respectively. In human serum, the accelerations were 800- and 450-fold compared to buffer. In striking contrast, the β,γ-(1-hydroxyethylidene) derivatives did not experience a similar decrease in hydrolytic stability. The stability in human serum was comparable to that in aqueous buffer (τ1/2 = 17 and 33 h with 4 and 6, respectively), and on going to mouse serum, a 2- to 4-fold acceleration was observed. To elucidate the mineral-binding properties of 4-7, their retention on a hydroxyapatite column was studied and compared to that of zoledronate (1a) and nucleoside mono-, di-, and triphosphates.